阿帕替尼在恶性肿瘤中的研究进展  

Research progress of apatinib on malignant tumor

作　　者：李祥[1] 郑红梅[1] 吴奇[2] 孙圣荣[2] 吴新红[1] 

机构地区：[1]湖北省肿瘤医院乳腺科,武汉430079 [2]武汉大学人民医院甲乳外科

出　　处：《临床外科杂志》2017年第4期314-315,共2页Journal of Clinical Surgery

基　　金：湖北省卫生计生委重点资助项目(WJ2015MA016)

摘　　要：近几年关于抗肿瘤血管生成药物的研究越来越多,血管内皮生长因子受体(vascular endothelial growth factor receptors,VEGFR)在血管形成过程起重要作用。阿帕替尼是一种新型口服小分子VEGFR酪氨酸激酶抑制剂(tyrosine kinase inhibitors,TKI),目前主要用于晚期胃癌、乳腺癌和肺癌等治疗,目前已进入Ⅲ期临床试验。相比于同类药物索拉非尼和舒尼替尼,阿帕替尼显现出更高的体外和体内活性,具有很强的抗肿瘤作用。本文就关于阿帕替尼的研究背景、临床研究和药物不良反应进行综述。In recent years,there were many reports involved in anti-angiogenesis drugs,vascular endothelial growth factor receptors（VEGFRs）which played a vital role in angiogenesis.Apatinib was known as a novel orally small-molecule VEGFR tyrosine kinase inhibitor,mainly used in the therapy of advanced refractory gastric cancer,breast cancer and lung cancer.Currently apatinib has entered phase Ⅲ clinical trials.It had stronger antineoplastic activity both in vivo and in vitro when compared with the similar drug such as sorafenib or sunitinib,which was comfirmed by a lot of basic and clinical research.In this article,background,basic information,pharmacodynamics,clinical trials and drug toxicity of apatinib will be discussed.

关 键 词：阿帕替尼 恶性肿瘤 不良反应 

分 类 号：R730.5[医药卫生—肿瘤]